Seattle Genetics Inc., of Bothell, Wash., reported that sales of its lymphoma therapy, Adcetris (brentuximab vedotin), hit $83.7 million in the fourth quarter, up 18 percent from net sales of $70.8 million in the fourth quarter of 2016.